食管鳞状细胞癌癌前病变的分子改变

摘要/Abstract

摘要：食管鳞状细胞癌是世界范围内最常见的恶性肿瘤之一，其发生具有较典型的癌前病变阶段。目前关于标志物的研究主要集中在核酸和蛋白水平，DNA水平包括基因组水平的遗传学改变、基因扩增、缺失、突变、断裂、融合，RNA水平包括mRNA、微小RNA（miRNA）、长非编码RNA（lncRNA）等的表达改变，蛋白水平包括表达水平、亚细胞定位以及翻译后的修饰等变化。鉴定早期食管鳞状细胞癌和癌前病变的分子改变，对于探索该病早期诊断的生物标志物和早期干预靶点均具有重要的意义。

关键词:食管肿瘤,肿瘤,鳞状细胞,DNA,RNA,蛋白质类,癌前病变

Abstract:Esophageal squamous cell carcinoma (ESCC) is one of the most predominant malignancies worldwide. ESCC develops gradually from the precancerous lesions. The researches about biomarkers mainly concentrate in the nucleic acid and protein, including cytogenetic abnormalities, amplifications, deletions, mutations, breakage and fusions of genomic DNA, expression changes of mRNA, microRNA (miRNA) and long noncoding RNA (lncRNA) in RNA level, and expression level, subcellular localization, and posttranslational modifications of proteins. Studies on the molecular alterations in precancerous lesions and early cancer of t he esophagus will contribute to the exploration of biomarkers for early diagnosis and intervention targets for this disease.

Key words:Esophageal neoplasms,Neoplasms, squamous cell,DNA,RNA,Proteins,Precancerous lesions

常晨，王明荣. 食管鳞状细胞癌癌前病变的分子改变[J]. 国际肿瘤学杂志, 2019, 46(7): 430-433.

Chang Chen, Wang Mingrong. Molecular alterations in precancerous lesions of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2019, 46(7): 430-433.

参考文献

［1］ Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer［J］. Nat Rev Dis Primers, 2017, 3: 17048. DOI: 10.1038/nrdp.2017.48. ［2］郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志, 2019, 41(1): 1928. DOI: 10.3760/cma.j.issn.02533766.2019.01.005. ［3］ Wei WQ, Chen ZF, He YT, et al. Longterm followup of a community assignment, onetime endoscopic screening study of esophageal cancer in China［J］. J Clin Oncol, 2015, 33(17): 19511957. DOI: 10.1200/JCO.2014.58.0423. ［4］ Singhi AD, Arnold CA, LamHimlin DM, et al. Targeted nextgeneration sequencing supports epidermoid metaplasia of the esophagus as a precursor to esophageal squamous neoplasia［J］. Mod Pathol, 2017, 30(11): 16131621. DOI: 10.1038/modpathol.2017.73. ［5］ Liu X, Zhang M, Ying S, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma［J］. Gastroenterology, 2017, 153(1): 166177. DOI: 10.1053/j.gastro.2017.03.033. ［6］ Chen XX, Zhong Q, Liu Y, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multiregion wholeexome sequencing［J］. Nat Commun, 2017, 8(1): 524. DOI: 10.1038/s41467017006500. ［7］ Shi ZZ, Shang L, Jiang YY, et al. Consistent and differential genetic aberrations between esophageal dysplasia and squamous cell carcinoma detected by array comparative genomic hybridization［J］. Clin Cancer Res, 2013, 19(21): 58675878. DOI: 10.1158/10780432.CCR123753. ［8］ Yang YF, Li H, Xu XQ, et al. An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis［J］. Dis Esophagus, 2008, 21(5): 395401. DOI: 10.1111/j.14422050.2007.00789.x. ［9］ Hu HB, Jie HY, Zheng XX. Three circulating lncRNA predict early progress of esophageal squamous cell carcinoma［J］. Cell Physiol Biochem, 2016, 40(12): 117125. DOI: 10.1159/000452529. ［10］ Liu Z, Yang T, Xu Z, et al. Upregulation of the long noncoding RNA BANCR correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma［J］. Biomed Pharmacother, 2016, 82: 406412. DOI: 10.1016/j.biopha.2016.05.014. ［11］ Cui XB, Zhang SM, Xu YX, et al. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma［J］. J Transl Med, 2016, 14(1): 137. DOI: 10.1186/s129670160884y. ［12］ Choy B, LaLonde A, Que J, et al. MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions［J］. Hum Pathol, 2016, 57: 126135. DOI: 10.1016/j.humpath.2016.07.013. ［13］ Peng J, Hu Q, Liu W, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma［J］. Diagn Pathol, 2013, 8: 177. DOI: 10.1186/174615968177. ［14］ Li M, Cui X, Shen Y, et al. ORAOV1 overexpression in esophageal squamous cell carcinoma and esophageal dysplasia: a possible biomarker of progression and poor prognosis in esophageal carcinoma［J］. Hum Pathol, 2015, 46(5): 707715. DOI: 10.1016/j.humpath.2015.01.009. ［15］ Cui XB, Shen YY, Jin TT, et al. SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma［J］. J Transl Med, 2015, 13: 321. DOI: 10.1186/s129670150681z. ［16］ Chen G, Xu R, Yue B, et al. The expression of podoplanin protein is a diagnostic marker to distinguish the early infiltration of esophageal squamous cell carcinoma［J］. Oncotarget, 2017, 8(12): 1901319020. DOI: 10.18632/oncotarget.14596. ［17］ Shang L, Hao JJ, Zhao XK, et al. ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction［J］. Oncotarget, 2016, 7(17): 2437424382. DOI: 10.18632/oncotarget.8223. ［18］ Yu J, Zheng Y, Han XP, et al. Threegene immunohistochemical panel predicts progression and unfavorable prognosis in esophageal squamous cell carcinoma［J］. Hum Pathol, 2018. pii: S00468177(18)304829. DOI: 10.1016/j.humpath.2018.11.027. ［19］ Zhang H, Li H, Ma Q, et al. Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program［J］. World J Gastroenterol, 2016, 22(39): 87708778. DOI: 10.3748/wjg.v22.i39.8770. ［20］ Zhou SL, Yue WB, Fan ZM, et al. Autoantibody detection to tumorassociated antigens of P53, IMP1, P16, cyclin B1, P62, Cmyc, Survivn, and Koc for the screening of highrisk subjects and early detection of esophageal squamous cell carcinoma［J］. Dis Esophagus, 2014, 27(8): 790797. DOI: 10.1111/dote.12145. ［21］ Pritchett NR, Burgert SL, Murphy GA, et al. Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya［J］. BMC Cancer, 2017, 17(1): 835. DOI: 10.1186/s1288501738379. ［22］ Abnet CC, Chen W, Dawsey SM, et al. Serum 25(OH)vitamin D concentration and risk of esophageal squamous dysplasia［J］. Cancer Epidemiol Biomarkers Prev, 2007, 16(9): 18891893. DOI: 10.1158/10559965.EPI070461. ［23］ Yu G, Gail MH, Shi J, et al. Association between upper digestive tract microbiota and cancerpredisposing states in the esophagus and stomach［J］. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 735741. DOI: 10.1158/10559965.EPI130855. ［24］ Chen X, Winckler B, Lu M, et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a highrisk area of China［J］. PLoS One, 2015, 10(12): e0143603. DOI: 10.1371/journal.pone.0143603.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.